Somatostatin analogues are the most clinically mature peptide-drug class that most readers of this reference will never have seen discussed outside a hospital formulary. Three analogues are in routine UK use — octreotide, lanreotide and pasireotide — and all three are licensed prescription medicines, not research reagents. That makes the class a useful mirror: it shows what a peptide hormone looks like after it has survived full development, patent expiry and a settled place in NHS shared-care protocols.
01 — The endogenous template: a hormone with a minutes-long half-life
Somatostatin (somatotropin release-inhibiting factor, SRIF) is a short regulatory peptide that acts as a broad inhibitor of secretion across the endocrine and exocrine systems. It circulates in two principal forms — somatostatin-14 and the N-terminally extended somatostatin-28 — and signals through five G-protein-coupled receptor subtypes, SSTR1 to SSTR5, expressed in a tissue-specific pattern. In the anterior pituitary it suppresses growth hormone (GH) and thyroid-stimulating hormone release; in the pancreas and gut it inhibits secretion of insulin, glucagon, gastrin and other gastroenteropancreatic peptides.
That breadth is precisely what limits its direct clinical use. Native somatostatin has a plasma half-life measured in minutes, so it is degraded before it can act usefully, and its undifferentiated receptor activity cannot be steered towards a single tissue. Every somatostatin analogue in clinical use is an attempt to solve the same two problems at once: extend the half-life, and bias receptor selectivity.
02 — How the analogues are engineered
The first-generation analogues preserve the pharmacophore — the β-turn tetrapeptide motif Phe-Trp-Lys-Thr and the disulfide bridge that constrains the ring — while altering the surrounding residues to resist peptidase degradation. D-amino acid substitutions and a shortened backbone make octreotide, a cyclic octapeptide, substantially more stable than the native hormone while retaining high affinity for SSTR2. Lanreotide follows the same structural logic with different residues around the core.
Selectivity is the second lever. Octreotide and lanreotide both bind SSTR2 with high affinity and SSTR5 more weakly, so their pharmacology is dominated by SSTR2-expressing tissue. Pasireotide, a cyclohexapeptide and the main second-generation analogue, was designed around a different observation — that corticotroph and some somatotroph tumours over-express SSTR5. It binds SSTR5 with the highest affinity, has markedly greater affinity than the first-generation analogues for SSTR1 and SSTR3, and correspondingly lower affinity for SSTR2. Same hormone mimicry, different receptor map, and therefore a different clinical profile.
03 — Half-life engineering and depot formulation
Because the native peptide is cleared within minutes, the analogues are delivered as depot injections rather than as free peptide. Octreotide is formulated in biodegradable polymer microspheres (octreotide LAR) that release over roughly four weeks; lanreotide is prepared as a supersaturated aqueous gel (lanreotide Autogel) that sustains exposure across a comparable interval; pasireotide LAR uses a comparable long-acting release technology. Immediate-release octreotide has a half-life of only a few hours, which is why the depot formulations — not the peptide sequence alone — define how the class behaves in practice.
This matters for anyone comparing these compounds with grey-market 'research peptides': the clinical behaviour of a somatostatin analogue depends as much on its formulation and release kinetics as on its receptor affinity.
04 — UK licensing and the legal position
Octreotide, lanreotide and pasireotide are prescription-only medicines (POM) under the Human Medicines Regulations 2012. They are licensed in the UK for defined indications: acromegaly, where surgery or radiotherapy is inappropriate, ineffective, or awaiting full effect; symptom control in functional gastroenteropancreatic neuroendocrine tumours (NETs), including carcinoid syndrome; and, for octreotide and lanreotide, advanced midgut NETs. Pasireotide is additionally licensed for Cushing's disease where pituitary surgery is not an option or has not been curative. NHS shared-care protocols for acromegaly — for example the Buckinghamshire, Oxfordshire and Berkshire West ICB protocol — name lanreotide (Somatuline Autogel) and octreotide (Sandostatin LAR and Olatuton) among first-line pharmacological options.
The legal position is the mirror image of the grey market. These are not research-use-only materials: they are fully licensed medicines that may be supplied only against a prescription, and possession or supply outside that framework is unlawful. The research-reagent framing that applies to most compounds in this reference does not apply here.
05 — What the evidence does and does not show
Within their licensed indications the somatostatin analogues rest on a large, mature clinical database — randomised trials, long-term extension studies and decades of NET registry experience — which is why the class carries a strong evidentiary footing for acromegaly and functional NET control. That evidence is indication-specific. It concerns biochemical control of GH/IGF-1 and symptom burden in patients with defined endocrine disease; it does not transfer to general metabolic, longevity or wellness uses, and no claim should be read that way.
The class also illustrates that efficacy is inseparable from tolerability. Common effects include gastrointestinal symptoms, biliary sludge and gallstones, and bradycardia; pasireotide carries a more prominent hyperglycaemia signal, reflecting its SSTR5-weighted pharmacology. Monitoring and any dose adjustment are matters for the prescribing clinician and the Summary of Product Characteristics, not for this reference.
06 — Why the class matters here
The somatostatin analogues are the clearest example in this reference of a peptide hormone that completed full clinical development. Compare them with the grey-market column — BPC-157, TB-500, the growth-hormone secretagogues — where deep preclinical literatures sit beside nearly empty human-data columns. The difference is not the chemistry; it is the presence of controlled trials, licensed indications and a regulatory footing. That contrast is the standard against which every research peptide in this reference is best read.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.